A phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) (BMS [Bristol-Myers Squibb] protocol 180129).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2012
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 07 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jan 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 06 May 2011 Planned End Date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.